Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry-Reference-Cited by-同舟云学术

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

Published:2015-04-24 Issue:3 Volume:170 Page:372-383
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

de Swart Louise¹,Smith Alex²,Johnston Thomas W.²,Haase Detlef³,Droste Jackie¹,Fenaux Pierre⁴,Symeonidis Argiris⁵,Sanz Guillermo⁶,Hellström-Lindberg Eva⁷,Cermák Jaroslav⁸,Germing Ulrich⁹,Stauder Reinhard¹⁰,Georgescu Otilia¹¹,MacKenzie Marius¹,Malcovati Luca¹²,Holm Mette S.¹³,Almeida Antonio M.¹⁴,Mądry Krzysztof¹⁵,Slama Borhane¹⁶,Guerci-Bresler Agnes¹⁷,Sanhes Laurence¹⁸,Beyne-Rauzy Odile¹⁹,Luño Elisa²⁰,Bowen David²¹,de Witte Theo²²

Affiliation:

1. Department of Haematology; Radboud University Medical Centre; Nijmegen The Netherlands

2. Epidemiology and Cancer Statistics Group; University of York; York UK

3. Department of Haematology and Oncology; Georg-August-University of Göttingen; Göttingen Germany

4. Service d'Hématologie; Hôpital Saint-Louis; Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7; Paris France

5. Department of Medicine; Divison of Haematology; University of Patras Medical School; Patras Greece

6. Department of Haematology; Hospital Universitario La Fe; Valencia Spain

7. Department of Medicine; Division of Haematology; Karolinska Institutet; Stockholm Sweden

8. Department of Clinical Haematology; Institute of Haematology & Blood Transfusion; Praha Czech Republic

9. Department Of Haematology, Oncology and Clinical Immunology; Universitätsklinik Düsseldorf; Düsseldorf Germany

10. Department of Internal Medicine V (Haematology and Oncology); Innsbruck Medical University; Innsbruck Austria

11. Center of Hematology and Bone Marrow Transplantation; Fundeni Clinical Institute; Bucharest Romania

12. Department of Haematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; University of Pavia; Pavia Italy

13. Department of Haematology; Aarhus University Hospital; Aarhus Denmark

14. Serviço d'Hematologia - Instituto Português de Oncologia de Lisboa; Lisbon Portugal

15. Department of Haematology, Oncology and Internal Medicine; Warszawa Medical University; Warszawa Poland

16. Service d'Hématologie; Centre Hospitalier d'Avignon; Avignon France

17. Service d'Hématologie; Centre Hospitalier Universtaire Brabois Vandoeuvre; Nancy France

18. Service d'Hématologie; Centre Hospitalier de Perpignan; Perpignan France

19. Service d'Hématologie; Centre Hospitalier Universitaire de Purpan; Toulouse France

20. Servicio d'Hematología; Servicio de Salud del Principado de Asturias; Oviedo Spain

21. St. James's Institute of Oncology; Leeds Teaching Hospitals; Leeds UK

22. Department of Tumor Immunology - Nijmegen; Institute for Molecular Life Sciences; Radboud university medical center; Nijmegen The Netherlands

Funder

Novartis

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13450/fullpdf

Reference39 articles.

1. New look at statistical-model identification;Akaike;Ieee Transactions on Automatic Control,1974

2. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes;Aul;British Journal of Haematology,1992

3. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes;Aul;Haematologica,1998

4. Clinical effect of point mutations in myelodysplastic syndromes;Bejar;New England Journal of Medicine,2011

5. World Health Organization classification of the acute leukemias and myelodysplastic syndrome;Bennett;International Journal of Hematology,2000

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How we diagnose Myelodysplastic syndromes;Frontiers in Oncology;2024-09-13

2. MDS patient registries - achievements and challenges;Annals of Hematology;2024-08-23

3. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe;Future Oncology;2024-08-14

4. Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS;2024-05-23

5. Inflammatory profile of lower risk myelodysplastic syndromes;British Journal of Haematology;2024-05-21